作　　者： ;

机构地区： 新疆医科大学第一附属医院

出　　处： 《中国防痨杂志》 2020年第4期398-403,共6页

摘　　要： 结核分枝杆菌作为一种巨噬细胞胞内寄生菌,传统药物治疗存在治疗周期长、生物利用度低、毒性大甚至耐药性增加等局限性问题.抗结核纳米递药系统作为一种抗结核新剂型,可将经济廉价的药物通过主动或被动方式递送到巨噬细胞内,以杀死正在复制或潜伏期的结核分枝杆菌.在此框架下,笔者探讨了抗结核纳米递药系统对巨噬细胞主被动靶向机制,及用于组装纳米递药系统的先进材料.此外,总结了影响靶向递送效率的因素及面临的挑战. Mycobacterium tuberculosis(MTB)is a facultative intracellular parasite of macrophages,traditional anti-TB therapy have limitations such as long course of treatment,low bio-availability,high systemic toxicity and even may induce drug resistance.As a new method of anti-tuberculous drug administration,the nanoscale drug delivery system can deliver low-cost drugs into macrophages actively or passively to inhibit the replicate or latent MTB.This review explores the active and passive targeting mechanism of anti-tuberculosis nanoscale drug delivery system to macrophages,and advanced materials for assembling nanoscale delivery system.In addition,factors affecting targeted delivery efficiency and challenges are summarized.

关 键 词： 结核 巨噬细胞 药物载体 分子靶向治疗 综述文献 主题 纳米递药系统

领　　域： []